HOWL241115C2500
- 0.70
- +0.15+27.27%
Werewolf Therapeutics Newsroom
BofA Securities Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Maintains Target Price $10
Analysts Offer Insights on Healthcare Companies: Werewolf Therapeutics (HOWL) and Chimerix (CMRX)
Leerink Partners Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Announces Target Price $13
Wedbush Adjusts Price Target on Werewolf Therapeutics to $8 From $9, Maintains Outperform Rating
Buy Rating Affirmed for Werewolf Therapeutics on Strong Candidate Progress and Promising Safety Profiles
Buy Rating Affirmed: Werewolf Therapeutics' Promising Pipeline and Financial Health
Werewolf Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Werewolf Therapeutics, Maintains $15 Price Target
Werewolf Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Werewolf Therapeutics, Maintains $15 Price Target
JMP Securities Reiterates Market Outperform on Werewolf Therapeutics, Maintains $12 Price Target
Werewolf Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Werewolf Therapeutics (HOWL), Eli Lilly & Co (LLY) and Envista Holdings (NVST)
Analysts' Top Healthcare Picks: Axsome Therapeutics (AXSM), Werewolf Therapeutics (HOWL)
Critical Insights From Werewolf Therapeutics Analyst Ratings: What You Need To Know
Werewolf Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Werewolf Therapeutics, Maintains $15 Price Target
Buy Rating Justified by Werewolf Therapeutics' Advancements in WTX-124 With Promising Efficacy and Safety Profile
Werewolf Therapeutics: Buy Rating Affirmed Amid Promising Clinical Advancements and Pipeline Potential
J.P. Morgan Securities: Reiterated the Werewolf Therapeutics (HOWL.US) rating and adjusted from superior to superior market rating, with a target price of $12.00.